Compare GameStop Corp. (GME) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Viatris Inc — how do they compare? GameStop Corp. trades at $22.12 (market cap $9.99B), while Viatris Inc trades at $17.19 (market cap $19.44B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.88% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | VTRS | |
|---|---|---|
Market Cap | $9.99B | $19.44B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $17.39 |
52-Week Low | $19.94 | $8.74 |
Enterprise Value | $5.96B | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.36, down 0.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue declined to $3.82 billion in 2025, but net income improved to $131.3 million, reflecting a profit margin of 3.43%. Recent developments include a partnership with Uber Eats and ongoing efforts to acquire eBay, as announced in Business Wire on June 26, 2026.
The outlook is mixed, with positive EBITDA guidance above $600 million for fiscal 2026 offering upside potential, but risks include revenue declines and dependence on physical media amid Sony's shift away from discs. Analyst sentiment is cautious, with only 16.67% buy ratings, suggesting limited near-term conviction despite operational improvements.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
